Evofem Biosciences Performance
| EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
The firm shows a Beta (market volatility) of -0.37, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Evofem Biosciences are expected to decrease at a much lower rate. During the bear market, Evofem Biosciences is likely to outperform the market. Evofem Biosciences right now shows a risk of 0.0%. Please confirm Evofem Biosciences potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Evofem Biosciences will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Evofem Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Evofem Biosciences is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 72.3 M | |
| Total Cashflows From Investing Activities | -2.7 M |
Evofem |
Evofem Biosciences Relative Risk vs. Return Landscape
If you would invest 4.79 in Evofem Biosciences on September 2, 2024 and sell it today you would earn a total of 0.00 from holding Evofem Biosciences or generate 0.0% return on investment over 90 days. Evofem Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Evofem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evofem Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evofem Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Evofem Biosciences, and traders can use it to determine the average amount a Evofem Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EVFM |
Based on monthly moving average Evofem Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evofem Biosciences by adding Evofem Biosciences to a well-diversified portfolio.
Evofem Biosciences Fundamentals Growth
Evofem OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Evofem Biosciences, and Evofem Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evofem OTC Stock performance.
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (5.41) % | ||||
| Current Valuation | 112.69 M | ||||
| Shares Outstanding | 121.22 M | ||||
| Price To Earning | (1.26) X | ||||
| Price To Book | 8.37 X | ||||
| Price To Sales | 0.42 X | ||||
| Revenue | 8.24 M | ||||
| EBITDA | (204.14 M) | ||||
| Cash And Equivalents | 19.89 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 125.74 M | ||||
| Debt To Equity | 8.72 % | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (146.67 M) | ||||
| Earnings Per Share | (19.01) X | ||||
| Total Asset | 42.51 M | ||||
| Retained Earnings | (526.68 M) | ||||
| Current Asset | 16.39 M | ||||
| Current Liabilities | 12.61 M | ||||
About Evofem Biosciences Performance
By examining Evofem Biosciences' fundamental ratios, stakeholders can obtain critical insights into Evofem Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evofem Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in womens sexual and reproductive health. Evofem Biosciences, Inc. is headquartered in San Diego, California. Evofem Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 119 people.Things to note about Evofem Biosciences performance evaluation
Checking the ongoing alerts about Evofem Biosciences for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Evofem Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evofem Biosciences is not yet fully synchronised with the market data | |
| Evofem Biosciences has some characteristics of a very speculative penny stock | |
| Evofem Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Evofem Biosciences currently holds 125.74 M in liabilities with Debt to Equity (D/E) ratio of 8.72, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evofem Biosciences has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Evofem Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evofem Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evofem Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evofem to invest in growth at high rates of return. When we think about Evofem Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 8.24 M. Net Loss for the year was (205.19 M) with profit before overhead, payroll, taxes, and interest of 4.19 M. | |
| Evofem Biosciences currently holds about 19.89 M in cash with (146.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Evofem Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evofem Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Evofem Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evofem Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evofem Biosciences' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Evofem Biosciences' otc stock. These opinions can provide insight into Evofem Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |